{"entity":{"id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SGT003 in advanced solid tumours, run by Beijing Sungen Biomedical Technology Co., Ltd, now recruiting.","summary":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07811037 by Beijing Sungen Biomedical Technology Co., Ltd, with 332 participants planned, started 2026-08-17 and due to reach its primary completion in 2028-12. Interventions recorded: SGT003.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07811037","url":"https://clinicaltrials.gov/study/NCT07811037"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07811037","phase":"1/2","setting":"A Multicenter, Dose-Escalation and Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","sponsor":"Beijing Sungen Biomedical Technology Co., Ltd","enrolled":332,"outcomes":[]},"route":"/trials/nct07811037/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}